Panacea Life Sciences Holdings, Inc. Announces Participation in Investor Summit Group's Q2 In-Person Conference
Panacea Life Sciences Holdings (OTCQB:PLSH) announced CEO Leslie Buttorff's participation in the Q2 Investor Summit Group on May 3-4, 2022, in New York City. Buttorff will present the company's growth roadmap during a session on May 3rd at 1:15 PM ET. The conference, aimed at connecting smallcap and microcap companies with investors, will also offer 1x1 meetings for qualified investors. Panacea is focused on cannabinoid-based products for various medical conditions and aims to rank among the top 10 U.S. firms in revenue and brand.
- Participation in investor conference may enhance investor relations.
- Focus on growth roadmap indicates potential for future expansion.
- Company's aim to be a top 10 U.S. cannabinoid company highlights growth ambitions.
- None.
GOLDEN, CO / ACCESSWIRE / May 3, 2022 / Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) is pleased to announce that Leslie Buttorff will be in attendance at The Q2 Investor Summit Group - In-Person. Panacea Life Sciences Holdings' Chief Executive Officer, Leslie Buttorff, will discuss the company's roadmap for growth in the next 1-2 years.
Event: | The Q2 Investor Summit Group |
|---|---|
Date: | May 3-4, 2022 |
Location: | The Westin New York Grand Central |
Presentation: | May 3rd at 1:15PM ET |
View webcast presentation: |
- 1x1s will be available for qualified investors
- The conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration
About Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) is a fully integrated FDA, cGMP certified, seed-to-sale cannabinoid product focused company. We research, develop, manufacture and commercialize raw materials derived from industrial hemp and custom formulate, manufacture and distribute softgels (both bovine and vegan), gummies, tinctures, sublingual tablets, patches, K-Tape, topical pain relief and skin care products as our base business. We have expanded our research and development preclinical and clinical programs, with a focus on nutraceutical and purposeful, natural pharmaceutical alternatives for humans and companion animals. We research, produce, and distribute products both domestically and internationally that target and treat major categories of medical conditions: pain, cancer, psychological, epilepsy, gastrointestinal, autoimmune, neurological, and sleep disorders and support these product through clinical research and studies. These categories include conditions that affect hundreds of millions of patients and animals worldwide.Our vision is to become the leading research and manufacturing cannabinoid and nutraceutical company (top 10 in terms of revenue and brand) in the U.S.
For further information:
Panacea Life Sciences Holdings, Inc.
Leslie Buttorff
3034340215
leslie.buttorff@panacealife.com
About the Investor Summit Group
The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit Group will take place in-person, featuring 65+ companies and over 300 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. info@investorsummitgroup.com
SOURCE: Panacea Life Sciences, Inc
View source version on accesswire.com:
https://www.accesswire.com/699840/Panacea-Life-Sciences-Holdings-Inc-Announces-Participation-in-Investor-Summit-Groups-Q2-In-Person-Conference
FAQ
When is Panacea Life Sciences participating in the Q2 Investor Summit?
What time will Panacea's presentation occur at the Investor Summit?
Where is the Q2 Investor Summit taking place?
What is the ticker symbol for Panacea Life Sciences?
What does Panacea Life Sciences focus on?
